Blog

March 2, 2021

Assessing the Real World Accuracy of ctDNA Diagnostics

Canexia Health's Chief Scientific Officer writes about the importance of combining different approaches to obtain correct results for ctDNA diagnostics. While high sensitivity is important, it must be contextualized with other key measurements.

Read More

Blog

November 13, 2020

Liquid Biopsy Offers New Hope for Ontario Family

Carla Van Wyck-MacDonald's cancer had progressed to an advanced stage before she was referred by her oncologist to get a liquid biopsy through Canexia's Project ACTT. The test revealed a mutation known as PIK3CA, which led to her enrolment in clinical trials for two targeted drugs.

Read More

Blog

November 9, 2020

4 Lessons for Late Stage Cancer Care During COVID-19

Brady Davis, Canexia's SVP of Corporate Development, moderated this workshop as part of the Association for Molecular Pathology 2020 conference, bringing together four global experts in oncology and pathology. Here are four key takeaways.

Read More

More Information at Your Fingertips

Every Canexia Health report comes with therapeutic recommendations based on specific gene mutations and patient profiles, with clinical trials reviewed and selected by certified clinical molecular geneticists.

Learn More